CV, Cancer Risk Up With Tofacitinib for Rheumatoid Arthritis

Incidences of major adverse cardiovascular events, cancers higher with tofacitinib versus TNF inhibitor; criteria for noninferiority not met.

Related Keywords

Minnesota , United States , Mayo Clinic In Rochester , Stevenr Ytterberg , , Pfizer , Healthday News , New England Journal , Mayo Clinic ,